Sichuan Kelun Pharmaceutical Co Ltd.
https://en.kelun.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sichuan Kelun Pharmaceutical Co Ltd.
Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter
Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Guangxi Kelun Pharmaceutical Co Ltd
- Hunan Kelun Pharmaceutical Co Ltd
- Hubei Kelun Pharmaceutical Co Ltd
- Kelun Pharmaceutical Group
- KLUS Pharma Inc
- Shandong Kelun Pharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Research Co Ltd
- Suzhou Kelun Pharmaceutical Research Co Ltd
- Sichuan Xindi Pharmaceutical Chemicals Co Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice